Comparative Efficacy and Future Directions in SCLC Treatment
Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them with second-line topotecan and CAV regimens, while discussing the potential of various compounds for platinum-sensitive vs platinum-resistant subgroups. He also considers the applicability of TIGIT immunotherapy, highlighting the need for robust clinical trial data on its safety and efficacy as both monotherapy and in combination, and he reflects on whether tiragolumab is more suited for chemotherapy-naive non–small cell lung cancer than for ES-SCLC, based on the phase 2 CITYSCAPE trial results.
Video content above is prompted by the following:
Do you envision clinical applicability of IO therapy with a T-cell immunoreceptor with immunoglobulin and immunoreceptor TIGIT for SCLC?
Given the ORR and PFS rates reported in the phase 2 CITYSCAPE trials, does tiragolumab coadministered with a PD-L1 inhibitor suggest it’s more likely to play a role in the treatment of chemotherapy-naive, PD-L1–positive, recurrent, or metastatic non–small cell lung cancer than in ES-SCLC?
